| abstract |
REFERS TO COMPOUNDS DERIVED FROM PIRAZOLE, FROM FORMULA (I) AND (II), WHERE Z 'IS O, S, AND NH; Q IS -NR4R5, -OH, ALKYL, ALKENYL, ALKINYL, CYCLOALKYL, AMONG OTHERS, OPTIONALLY REPLACED; R1, R2 AND R3 ARE INDEPENDENTLY, H, ALKYL, ALKENYL, ALKINYL, ARYL, CYCLOALKYL, HETEROARYL AND HETEROCYCLE, OPTIONALLY SUBSTITUTED; R4 AND R5 ARE H, ALKYL, ALCOXY, AMONG OTHERS, OPTIONALLY SUBSTITUTED, OR TOGETHER WITH THE N TO WHICH THEY ARE UNITED FORM A HETEROCYCLE, HETEROARYL, OPTIONALLY SUBSTITUTED; X IS H, HALOGEN, OPTIONALLY SUBSTITUTED RENT, NITRO, CYANE, OH, AMONG OTHERS. PREFERRED COMPOUNDS ARE: [2- (1-METHYL-PIPERIDIN-4-IL) -ETHYL] -AMIDE OF THE ACID 4-BROMO-5- (2-CHLORO-BENZOYLAMINO) -1H-PIRAZOL-3-CARBOXILICO, BECILAMIDA DEL ACIDO 4-BROMO-5- (2-CHLORO-BENZOYLAMINE) -1H-PIRAZOL-3-CARBOXYL, (2-OXO-AZEPAN-3-IL) -AMIDE OF ACID (R) -4-BROMO-5- (2- CHLORO-BENZOYLAMINE) -1-PHENYL-PIRAZOL-3-CARBOXYL, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. THESE COMPOUNDS ARE SELECTIVE ANTAGONISTS OF BRADIQUININ B1 RECEPTORS AND ARE USEFUL TO MODERATE PAIN, INFLAMMATION, SEPTIC ATTACK, HEALING, AMONG OTHERS |